{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:35:01Z","timestamp":1791268501076,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.yexcr.2011.08.021","type":"journal-article","created":{"date-parts":[[2011,9,9]],"date-time":"2011-09-09T03:57:58Z","timestamp":1315540678000},"page":"2765-2771","source":"Crossref","is-referenced-by-count":92,"title":["EGFR-targeted therapy"],"prefix":"10.1016","volume":"317","author":[{"given":"Loredana","family":"Vecchione","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Normanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fortunato","family":"Ciardiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Tejpar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexcr.2011.08.021_bb0005","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Ciardiello","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.yexcr.2011.08.021_bb0010","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.yexcr.2008.10.043","article-title":"ERBBs in the gastrointestinal tract: recent progress and new perspectives","volume":"315","author":"Fiske","year":"2009","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0015","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/annonc\/mdl498","article-title":"Estimates of the cancer incidence and mortality in Europe in 2006","volume":"18","author":"Ferlay","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0020","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1200\/JCO.2008.17.6453","article-title":"Urgent need for a new staging system in advanced colorectal cancer","volume":"26","author":"Poston","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0025","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM198809013190901","article-title":"Genetic alterations during colorectal-tumor development","volume":"319","author":"Vogelstein","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0030","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/gut.2009.206250","article-title":"Colorectal cancer molecular biology moves into clinical practice","volume":"60","author":"Pritchard","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.yexcr.2011.08.021_bb0035","series-title":"Cancer\u2014Principles and Practice of Oncology","first-page":"971","article-title":"Molecular biology of gastrointestinal cancers","author":"Rosen","year":"1997"},{"issue":"5853","key":"10.1016\/j.yexcr.2011.08.021_bb0040","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1126\/science.1145720","article-title":"The genomic landscape of human breast and colon cancers","volume":"318","author":"Wood","year":"2007","journal-title":"Science"},{"issue":"Suppl. 4","key":"10.1016\/j.yexcr.2011.08.021_bb0045","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0959-8049(01)00230-1","article-title":"The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities","volume":"37","author":"Yarden","year":"2001","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.yexcr.2011.08.021_bb0050","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.yexcr.2011.08.021_bb0055","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1073\/pnas.032678499","article-title":"Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis","volume":"99","author":"Roberts","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"3 Pt 1","key":"10.1016\/j.yexcr.2011.08.021_bb0060","first-page":"G533","article-title":"Intestinal overexpression of EGF in transgenic mice enhances adaptation after small bowel resection","volume":"277","author":"Erwin","year":"1999","journal-title":"Am. J. Physiol."},{"issue":"7244","key":"10.1016\/j.yexcr.2011.08.021_bb0065","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nature07935","article-title":"Single Lgr5 stem cells build crypt\u2013villus structures in vitro without a mesenchymal niche","volume":"459","author":"Sato","year":"2009","journal-title":"Nature"},{"issue":"7330","key":"10.1016\/j.yexcr.2011.08.021_bb0070","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature09637","article-title":"Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts","volume":"469","author":"Sato","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.yexcr.2011.08.021_bb0075","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jama.298.1.70","article-title":"Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas","volume":"298","author":"Karamouzis","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.yexcr.2011.08.021_bb0080","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1634\/theoncologist.12-7-840","article-title":"Erlotinib in non-small cell lung cancer treatment: current status and future development","volume":"12","author":"Gridelli","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.yexcr.2011.08.021_bb0085","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1158\/1078-0432.CCR-07-0065","article-title":"Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one?","volume":"13","author":"Messersmith","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0090","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1470-2045(03)01137-9","article-title":"Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer","volume":"4","author":"Sridhar","year":"2003","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0095","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1038\/sj.onc.1210381","article-title":"Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer","volume":"26","author":"Galizia","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.yexcr.2011.08.021_bb0100","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","article-title":"Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor","volume":"22","author":"Saltz","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0105","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2005.08.037","article-title":"Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry","volume":"23","author":"Chung","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0110","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0115","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/327293a0","article-title":"Prevalence of ras gene mutations in human colorectal cancers","volume":"327","author":"Bos","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.yexcr.2011.08.021_bb0120","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1634\/theoncologist.2008-0181","article-title":"High concordance of Kras status between primary colorectal tumors and related metastatic sites: implications for clinical practice","volume":"13","author":"Santini","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.yexcr.2011.08.021_bb0125","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1200\/JCO.2008.18.7286","article-title":"Mutations of Kras and BRAF in primary and matched metastatic sites of colorectal cancer","volume":"26","author":"Artale","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0135","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrc2109","article-title":"Hyperactive ras in developmental disorders and cancer","volume":"7","author":"Schubbert","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.yexcr.2011.08.021_bb0140","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1158\/0008-5472.CAN-06-4158","article-title":"Oncogenic activation of the RAS\/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies","volume":"67","author":"Benvenuti","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0145","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/sj.bjc.6603685","article-title":"Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy","volume":"96","author":"Di Fiore","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.yexcr.2011.08.021_bb0150","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdm496","article-title":"KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab","volume":"19","author":"De Roock","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0155","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karapetis","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0160","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1200\/JCO.2007.12.5906","article-title":"KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab","volume":"26","author":"Li\u00e8vre","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0165","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"26","author":"Amado","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0175","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","article-title":"Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer","volume":"27","author":"Bokemeyer","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0180","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0185","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S1359-6349(09)72039-7","article-title":"Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial","volume":"7","author":"Douillard","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"16","key":"10.1016\/j.yexcr.2011.08.021_bb0190","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1001\/jama.2010.1535","article-title":"Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab","volume":"304","author":"De Roock","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.yexcr.2011.08.021_bb0195","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1056\/NEJMc0904160","article-title":"BRAF mutation in metastatic colorectal cancer","volume":"361","author":"Tol","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0200","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1200\/JCO.2008.18.0786","article-title":"Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer","volume":"26","author":"Di Nicolantonio","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0205","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/sj.bjc.6605177","article-title":"KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer","volume":"101","author":"Loupakis","year":"2009","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.yexcr.2011.08.021_bb0210","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","article-title":"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemo-refractory metastatic colorectal cancer: a retrospective Consortium analysis","volume":"11","author":"De Roock","year":"2010","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.yexcr.2011.08.021_bb0215","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1200\/JCO.2009.23.3452","article-title":"Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial","volume":"28","author":"Roth","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0220","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/0008-5472.CAN-08-2466","article-title":"PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies","volume":"69","author":"Roth","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0225","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1158\/1078-0432.CCR-08-2961","article-title":"PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer","volume":"15","author":"Prenen","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0230","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/annonc\/mdn541","article-title":"PI3KCA\/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients","volume":"20","author":"Perrone","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0235","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/sj.bjc.6604009","article-title":"PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients","volume":"97","author":"Frattini","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.yexcr.2011.08.021_bb0240","series-title":"American Association for cancer research 101st Annual meeting, April 17\u201321","article-title":"Use of massively parallel, nextgeneration sequencing to identify gene mutations beyond Kras that predict response to panitumumab in a randomized, phase 3, monotherapy study of metastatic colorectal cancer (mCRC)","author":"Peeters","year":"2010"},{"key":"10.1016\/j.yexcr.2011.08.021_bb0245","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2005.08.037","article-title":"Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry","volume":"23","author":"Chung","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0250","doi-asserted-by":"crossref","first-page":"157s","DOI":"10.1200\/jco.2006.24.18_suppl.3547","article-title":"Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1\u20139%) or negative (<1%) levels of epidermal growth factor receptor (EGFR)","volume":"24","author":"Hecht","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0255","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1470-2045(05)70102-9","article-title":"Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study","volume":"6","author":"Moroni","year":"2005","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0260","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/annonc\/mdm492","article-title":"EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients","volume":"19","author":"Cappuzzo","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0265","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-08-0449","article-title":"Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study","volume":"14","author":"Personeni","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0270","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1200\/JCO.2006.10.5437","article-title":"Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab","volume":"25","author":"Khambata-Ford","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0275","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1200\/JCO.2008.21.3744","article-title":"Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab","volume":"27","author":"Jacobs","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0280","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1200\/JCO.2009.22.6043","article-title":"Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study","volume":"28","author":"Tabernero","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0285","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/sj.bjc.6606054","article-title":"Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer","volume":"104","author":"Baker","year":"2011","journal-title":"BJC"},{"key":"10.1016\/j.yexcr.2011.08.021_bb0290","unstructured":"D. Rhodes, W.L. Banka, A.M. Chinnaiyan. Gene expression modules associated with cetuximab response in metastatic colorectal cancer predict additional patient populations likely to respond. (Personal communication)."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0295","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.3505","article-title":"Mutant KRAS and BRAF gene expression profiles in colorectal cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial","volume":"28","author":"Tejpar","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2011.08.021_bb0300","series-title":"ASCO Ann Meeting Proc: Chicago, IL","author":"Jonker","year":"2009"},{"issue":"6","key":"10.1016\/j.yexcr.2011.08.021_bb0305","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-09-1577","article-title":"Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)","volume":"70","author":"Dry","year":"2010","journal-title":"Cancer Res."}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482711003442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482711003442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T12:23:02Z","timestamp":1592914982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482711003442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":59,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0014482711003442"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2011.08.021","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}